Top news of the week: 26.05.2021.
Companies And Industries
Cancer Biotech Janux Therapeutics Files for $100 Million IPO
Janux plans to use the funds raised from the IPO to submit four Investigational New Drug applications to the U.S. FDA in the first half of 2022.
Kintor’s Proxalutamide is Bolsonaro’s Newest Answer to Brazil’s COVID-19 Crisis
Proxalutamide,aselectivehigh-affinitysilentantagonistoftheandrogenreceptor,isbeingdevelopedbyChinesebiotech,KintorPharmaceuticalLimited(9939.HK).
The Dish’s Weekly Biotechnology News Wrap Up – May 21, 2021
*|RSSFEED:DATE|* Incase you missed it. We summarized the week's top biotechnology stories.
UK competition watchdog probes AstraZeneca, Alexion merger
After a green light in the US, UK competition authority starts its own review of AstraZeneca's $39 billion takeover of Alexion
Book traversal links for The top 15 highest-paid biopharma CEOs of 2020
As COVID-19 vaccines and therapeutics reach the public, the companies involved in the pandemic fight have laid out some eye-popping pay packages for their chief executives. One in ...
Listen: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity
We discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes.
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
A phase 2b trial of NGM Biopharmaceuticals’ aldafermin in nonalcoholic steatohepatitis has missed its primary endpoint, sending shares in the biotech tumbling. NGM has pulled plans to enter ...
Self-Organizing, Beating Chambered Human Heart Cardioids Offer New Model for Research
Researchers hope human cardioid platform will enable development of mature, complex heart models for drug discovery and regenerative medicine research.